ANCA vasculitis
Amgen completes acquisition of ChemoCentryx in deal worth $3.7bn
Amgen gains access to the biopharma’s autoimmune disease treatment Tavneos
Amgen to acquire ChemoCentryx in $3.7bn cash deal
The agreement includes the acquisition of ChemoCentryx’s autoimmune disease treatment Tavneos
ChemoCentryx surges on phase 3 vasculitis study
Shares in the US biotech rose 227% after announcing trial results
GSK hands back rights to ChemoCentryx drug
Investigational IBD treatment vercirnon disappoints in phase III